Related Experiment Videos
Highly loaded nanoparticulate carrier using an hydrophobic antisense oligonucleotide complex
M Berton1, E Allémann, C A Stein
1School of Pharmacy, University of Geneva, quai E.-Ansermet CH-1211, Geneva, Switzerland.
Summary
Researchers developed nanoparticle drug delivery for HIV-1 gene therapy. This method efficiently loads antisense oligonucleotides into nanoparticles, preserving their integrity for potential therapeutic applications.
Area of Science:
- Pharmaceutical Nanotechnology
- Gene Therapy Delivery Systems
- Antisense Oligonucleotide Therapeutics
Background:
- Antisense oligonucleotides (AOs) with phosphorothioate backbones show promise as gene-specific therapies.
- Targeting AOs to HIV-1-infected cells like macrophages is a key therapeutic goal.
- Entrapping hydrophilic AOs into polymeric nanoparticles presents formulation challenges.
Purpose of the Study:
- To prepare and characterize AO-loaded nanoparticles for targeted HIV-1 therapy.
- To overcome the challenge of incorporating hydrophilic AOs into polymeric carriers.
- To achieve high AO loading and entrapment efficiency in nanoparticles.
Main Methods:
- Complexation of AOs with cetyltrimethylammonium bromide (CTAB).
- Preparation of AO-loaded nanoparticles using the emulsification-diffusion method.
- Purification and characterization of the final freeze-dried nanoparticle product.
Main Results:
- Achieved high oligonucleotide loading compared to previous studies.
- A 4% initial AO content resulted in 1.9% final loading with 47% entrapment efficiency.
- The integrity of both the oligonucleotide and the polymer was maintained in the freeze-dried product.
Conclusions:
- The developed method enables efficient loading of AOs into nanoparticles.
- This approach is promising for developing targeted gene therapies for HIV-1.
- Preservation of molecular integrity is crucial for therapeutic efficacy.